The closing price of PTC Therapeutics Inc (NASDAQ: PTCT) was $26.91 for the day, down -2.50% from the previous closing price of $27.60. In other words, the price has decreased by -$0.69 from its previous closing price. On the day, 533488 shares were traded.
Ratios:
Our analysis of PTCT’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.97 and its Current Ratio is at 2.02.
On December 08, 2023, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $37.
Oppenheimer Upgraded its Perform to Outperform on October 30, 2023, while the target price for the stock was maintained at $165.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 02 ’24 when Golden Lee Scott sold 526 shares for $28.37 per share. The transaction valued at 14,923 led to the insider holds 59,988 shares of the business.
Boulding Mark Elliott sold 794 shares of PTCT for $21,637 on Jan 30 ’24. The EXEC. VP AND CLO now owns 71,189 shares after completing the transaction at $27.25 per share. On Jan 30 ’24, another insider, Almstead Neil Gregory, who serves as the CHIEF TECHNICAL OPS OFFICER of the company, sold 618 shares for $27.25 each. As a result, the insider received 16,841 and left with 61,202 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTCT now has a Market Capitalization of 2.11B and an Enterprise Value of 3.47B. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.20. Its current Enterprise Value per Revenue stands at 3.70 whereas that against EBITDA is -10.49.
Stock Price History:
Over the past 52 weeks, PTCT has reached a high of $59.84, while it has fallen to a 52-week low of $17.53. The 50-Day Moving Average of the stock is 28.04, while the 200-Day Moving Average is calculated to be 29.67.
Shares Statistics:
PTCT traded an average of 941.30K shares per day over the past three months and 628.08k shares per day over the past ten days. A total of 75.71M shares are outstanding, with a floating share count of 73.71M. Insiders hold about 3.85% of the company’s shares, while institutions hold 110.35% stake in the company. Shares short for PTCT as of Mar 15, 2024 were 10.89M with a Short Ratio of 10.90, compared to 10.38M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 14.21% and a Short% of Float of 19.15%.
Earnings Estimates
The firm’s stock currently is rated by 13 analysts. On average, analysts expect EPS of -$1.25 for the current quarter, with a high estimate of -$0.56 and a low estimate of -$1.93, while EPS last year was -$1.88. The consensus estimate for the next quarter is -$1.54, with high estimates of -$1.06 and low estimates of -$2.66.
Analysts are recommending an EPS of between -$2.66 and -$8.45 for the fiscal current year, implying an average EPS of -$5.88. EPS for the following year is -$4.97, with 14 analysts recommending between -$1.95 and -$9.16.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 10 analysts. It ranges from a high estimate of $209.6M to a low estimate of $143.5M. As of the current estimate, PTC Therapeutics Inc’s year-ago sales were $220.38M, an estimated decrease of -22.70% from the year-ago figure. For the next quarter, 10 analysts are estimating revenue of $149.01M, a decrease of -30.30% less than the figure of -$22.70% in the same quarter last year. There is a high estimate of $169.37M for the next quarter, whereas the lowest estimate is $136.5M.
A total of 13 analysts have provided revenue estimates for PTCT’s current fiscal year. The highest revenue estimate was $675.8M, while the lowest revenue estimate was $469.7M, resulting in an average revenue estimate of $607.16M. In the same quarter a year ago, actual revenue was $937.82M, down -35.30% from the average estimate. Based on 13 analysts’ estimates, the company’s revenue will be $624.46M in the next fiscal year. The high estimate is $757.29M and the low estimate is $332.8M. The average revenue growth estimate for next year is up 2.80% from the average revenue estimate for this year.
